|
Malignant neoplasm of lung
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
CTD_human |
Genetically engineered murine models of mutant EGFR and KRAS have been developed that more accurately recapitulate human lung cancer.
|
18927287 |
2008 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
CTD_human |
Intermittent chemotherapy and erlotinib for nonsmokers or light smokers with advanced adenocarcinoma of the lung: a phase II clinical trial.
|
21541241 |
2011 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
CTD_human |
The Egfr and K-ras gene mutations were detected at sites also found in human lung cancers with low incidences, while the Egfr gene mutation was detected for the first time in chemical lung carcinogenesis of animals.
|
19336973 |
2009 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
CTD_human |
This study calls for revisiting the prevailing single-gene driver-oncogene view and links clinical outcomes to co-occurring genetic alterations in patients with advanced-stage EGFR-mutant lung cancer.
|
29106415 |
2017 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
CTD_human |
Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells.
|
23523951 |
2013 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
CTD_human |
Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents.
|
27935865 |
2017 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
CTD_human |
Epidermal growth factor receptor (EGFR) and MET are molecular targets for lung cancer treatment.
|
20934974 |
2010 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
-The National Cancer Care Network and the combined College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology guidelines indicate that all lung adenocarcinomas (ADCs) should be tested for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements.
|
27552093 |
2016 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this study, we determined the effects of T0901317 and/or an EGFR-TKI on the lung cancer cell lines A549 and HCC827-8-1 in vitro and in vivo.
|
30724772 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
EGFR mutation status was not correlated with R497KEGFR genotype of lung cancers.
|
18726117 |
2009 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
One-hundred and fifty two patients with activating EGFR mutations were included in this study and 136 patients' tumor sample were available for targeted sequencing of genomic alterations in 22 genes using the Colon and Lung Cancer panel (Ampliseq, Life Technologies).
|
27121209 |
2016 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We analyzed gene expression profiles of gefitinib-resistant PC9M2 cells that were derived from gefitinib-sensitive lung cancer PC9 cells and do not have known resistance mechanisms including EGFR mutation T790M.
|
26268703 |
2015 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Conversion of MIG6 peptide from the nonbinder to binder of lung cancer-related EGFR by phosphorylation and cyclization.
|
27346601 |
2017 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the epidermal growth factor receptor gene (EGFR) in lung cancers predict for sensitivity to EGFR kinase inhibitors.
|
25326805 |
2014 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
About half of the Japanese patients with lung cancers harbor an activating mutation of the epidermal growth factor receptor gene and they are very sensitive to epidermal growth factor receptor tyrosine kinase inhibitors.
|
20031962 |
2010 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity.
|
24885886 |
2014 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Chemotherapeutics-resistance "arms" race: An update on mechanisms involved in resistance limiting EGFR inhibitors in lung cancer.
|
28782530 |
2017 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the present study, we analyzed the mitochondria proteomics of lung cancer cell lines with different invasion abilities and found that EGFR is highly expressed in the mitochondria of highly invasive non-small-cell lung cancer (NSCLC) cells.
|
26497368 |
2015 |
|
Malignant neoplasm of lung
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
lncRNA LINC00152 knockdown had effects to suppress biological activity of lung cancer via EGFR/PI3K/AKT pathway.
|
28787699 |
2017 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
To identify the potential mechanisms of resistance, we established cell lines resistant to EGFR-TKIs from the human lung cancer cell lines PC9 and11-18, which harbored activating EGFR mutations.
|
22815900 |
2012 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The results of our grouped testing approach with optimized biosensors were consistent with that of direct sequencing, suggesting that our proposed protocol can be excellent candidate for genotyping of EGFR mutations in lung cancer patients.
|
29245087 |
2018 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
|
19898258 |
2010 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this study, we have investigated the erbB3 mRNA levels in reference to clinicopathologic data and EGFR mutation status in Japanese lung cancer specimens.
|
17631905 |
2008 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our observations show that EGFR-T790M provides a proliferative advantage with respect to WT EGFR and suggest that the enhanced kinase activity of this mutant is the basis for rare cases of inherited susceptibility to lung cancer.
|
17510392 |
2007 |